Share on StockTwits

Akers Biosciences (NASDAQ:AKER) VP Gary M. Rauch bought 1,020 shares of Akers Biosciences stock on the open market in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average price of $3.15 per share, with a total value of $3,213.00. Following the acquisition, the vice president now directly owns 1,500 shares in the company, valued at approximately $4,725. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Separately, analysts at Aegis initiated coverage on shares of Akers Biosciences in a research note on Monday, June 9th. They set a “buy” rating and a $11.00 price target on the stock.

Shares of Akers Biosciences (NASDAQ:AKER) traded down 6.03% during mid-day trading on Monday, hitting $2.96. The stock had a trading volume of 9,255 shares. Akers Biosciences has a 1-year low of $2.56 and a 1-year high of $5.52. The stock’s 50-day moving average is $3.69 and its 200-day moving average is $4.11. The company’s market cap is $14.5 million.

Akers Biosciences (NASDAQ:AKER) last released its earnings data on Tuesday, August 12th. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.16) by $0.06. Analysts expect that Akers Biosciences will post $-0.66 EPS for the current fiscal year.

Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.